NOVAVAX
Bookmark
ShareNOVAVAX is a company. It is in Gaithersburg, the United States and it has a male CEO called Stanley Charles Erck. It was founded in 1987 and is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Gaithersburg
- state: MD
- country: United States
- employees: 1,541 people
- revenues: 1.4B $
- sector: Health Care
- industry: Biotechnology
- foundation year: 1987
- CEO: Stanley Charles Erck
- CEO gender: male
- ESG score: Try Pro to see estimate
- environmental score (ESG): Try Pro to see estimate
- social score (ESG): Try Pro to see estimate
- governance score (ESG): Try Pro to see estimate
See more facts
Extract data
Download datasets about NOVAVAX:
Dataset of stocks from NOVAVAX:
NOVAVAX is one of the companies in Biotechnology, companies in Health Care, companies in Gaithersburg, companies in the United States and 3,456,835 companies in our database.
Talking Points
- Creating vaccines and driving value through partnerships and R&D | Novavax
- Novavax is a global biotechnology company with a proven vaccine technology, focused on developing our R&D assets and establishing partnerships to help protect health.
- Producing next-generation vaccines with global access for more people. See what’s developing at https://t.co/apuZo0qpnM.
- Producing next-generation vaccines with global access for more people. ... Jobs at NOVAVAX INC Manager, Biostatistics ... CureVac Biotechnology Tübingen, Baden-Württemberg Johnson & Johnson Hospital & Health Care ...
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
- Committed to creating vaccines to help protect health | Novavax
- We are a biotechnology company committed to addressing serious infectious diseases globally through the discovery and development of innovative vaccines.
- New Era of Revolutionary Vaccines EUA in the USA | Novavax
